Expert oncologists reflect on the state of molecular testing in non–small cell lung cancer and how it informs the management of patients with uncommon EGFR mutations.
June 30th 2023
Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.
July 7th 2023
Shared perspective on the armamentarium of molecular testing assays in non–small cell lung cancer and how results can be best interpreted when selecting treatment.
A brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.
July 14th 2023
Experts Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, highlight current understandings of EGFR mutation classifications in the context of non–small cell lung cancer.
Focused discussion on uncommon EGFR mutations in non–small cell lung cancer and concurrent treatment options in this setting.
July 21st 2023
Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, reflect on their experience managing real-world patients with uncommon EGFR mutations in non–small cell lung cancer.
Closing out their discussion on uncommon EGFR mutations in non–small cell lung cancer, Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, consider how the treatment paradigm will continue to evolve.